Theravance Biopharma, Inc. (TBPH)

Theravance Biopharma Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Oct 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	720	463	560	755	814	1,137
Market Cap Growth	78.88%	-17.33%	-25.82%	-7.35%	-28.37%	-22.63%
Enterprise Value	428	416	477	320	1,269	1,398
Last Close Price	14.30	9.41	11.24	11.22	11.05	17.77
PE Ratio	55.89	-	-	0.87	-	-
PS Ratio	9.18	7.19	9.75	14.70	14.72	15.82
PB Ratio	3.20	2.64	2.63	1.71	-2.40	-3.74
P/TBV Ratio	3.20	2.64	2.63	1.71	-	-
EV/Sales Ratio	5.54	6.47	8.30	6.23	22.95	19.46
Debt / Equity Ratio	0.21	0.28	0.23	0.12	-1.98	-2.23
Asset Turnover	0.20	0.18	0.12	0.11	0.13	0.16
Quick Ratio	6.60	4.89	4.84	11.99	3.20	2.93
Current Ratio	6.71	5.02	5.39	12.31	4.26	3.18
Return on Equity (ROE)	6.23%	-29.04%	-16.86%	-179.84%	-	-
Return on Assets (ROA)	-5.65%	-7.21%	-6.78%	-10.07%	-35.20%	-42.38%
Return on Capital (ROIC)	-8.71%	-10.88%	-8.87%	-11.99%	-42.23%	-56.44%
Earnings Yield	1.81%	-12.19%	-9.86%	115.58%	-24.49%	-24.45%
FCF Yield	33.99%	-2.56%	-5.27%	-24.86%	-25.94%	-22.61%
Buyback Yield / Dilution	-0.54%	11.67%	24.85%	-5.95%	-11.41%	-12.11%

Updated Aug 12, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q